Provided by Tiger Trade Technology Pte. Ltd.

60 degrees pharmaceuticals, Inc.

0.9734
-0.0067-0.68%
Post-market: 0.99530.0219+2.25%19:41 EST
Volume:159.70K
Turnover:160.41K
Market Cap:4.12M
PE:-0.12
High:1.04
Open:0.9804
Low:0.9600
Close:0.9801
52wk High:12.45
52wk Low:0.8500
Shares:4.23M
Float Shares:3.67M
Volume Ratio:4.21
T/O Rate:4.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.9044
EPS(LYR):-18.5454
ROE:-154.77%
ROA:-70.04%
PB:-0.80
PE(LYR):-0.05

Loading ...

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire
·
Sep 03

60 Degrees Pharm Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Sep 03

60 Degrees Pharmaceuticals Inc. Announces Date for Annual Stockholders Meeting

Reuters
·
Aug 27

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire
·
Aug 21

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

GlobeNewswire
·
Aug 19

60 Degrees Pharmaceuticals Inc. Announces Date for Annual Meeting of Stockholders

Reuters
·
Aug 16

60 Degrees Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for COO Kristen Landon

Reuters
·
Aug 15

60 Degrees Q2 EPS $(1.25) Misses $(0.96) Estimate, Sales $101.000K Miss $301.000K Estimate

Benzinga
·
Aug 14

60 Degrees Pharmaceuticals Q2 EPS USD -1.25

THOMSON REUTERS
·
Aug 14

60 Degrees Pharmaceuticals Inc - Expect to Remain Financially Viable Through March 31, 2026

THOMSON REUTERS
·
Aug 14

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

GlobeNewswire
·
Aug 14

60 Degrees Pharmaceuticals Announces $5 Million Public Offering with Potential Additional $5 Million from Warrant Exercises

Reuters
·
Jul 19

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

GlobeNewswire
·
Jul 17

Press Release: 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Dow Jones
·
Jul 17

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

GlobeNewswire
·
Jul 15

Director Cheryl Xu Reports Acquisition of Common Shares in 60 Degrees Pharmaceuticals Inc

Reuters
·
Jun 06